The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design (Q44313576)

1 December 2017

title

The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design (English)

1 reference

1 December 2017

1 reference

Nish Chaturvedi

1

1 reference

1 December 2017

Anne Katrin Sjoelie

series ordinal

2

1 reference

1 December 2017

Anders Svensson

series ordinal

3

1 reference

1 December 2017

DIRECT Programme Study Group

series ordinal

4

1 reference

1 December 2017

publication date

1 December 2002

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

1 December 2017

published in

1 reference

1 December 2017

volume

3

1 reference

1 December 2017

issue

4

1 reference

1 December 2017

page(s)

255-261

1 reference

Diabetic control and complications

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

When should ACE inhibitors be given to normotensive patients with IDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

Prevention of diabetic renal disease with special reference to microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

A stochastic model for the analysis of bivariate longitudinal AIDS data

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2002.047

21 January 2018

Identifiers

DOI

10.3317/JRAAS.2002.047

1 reference

1 December 2017

1 reference